SIETES :: 93213 citas

1 a 10 de 10

Presentar resultados

Seleccionar todas

Castells MC, Phillips EJ. Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 2020;383:30 de diciembre. [Ref.ID 103836]

Hababi S, Heinrich A, Omer SB. No-fault compensation for vaccine injury — The other side of equitable access to covid-19 vaccines. N Engl J Med 2020;383:3 de diciembre. [Ref.ID 103803]

Anónimo. FDA drug safety communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie. U.S. Food and Drug Administration 2015:22 de octubre. [Ref.ID 99573]

Anónimo. DPP-4 Inhibitors for type 2 diabetes: drug safety communication - May cause severe joint pain. U.S. Food and Drug Administration 2015:28 de agosto. [Ref.ID 99420]

Anónimo. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. U.S. Food and Drug Administration 2015:15 de mayo. [Ref.ID 99051]

Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368:1272-4. [Ref.ID 95242]

DeStefano F, Tokars J. H1N1 vaccine safety monitoring: beyond background rates. Lancet 2010;375:1146-7. [Ref.ID 88231]

Anónimo. Safety of influenza A (H1N1) 2009 monovalent vaccines — United States, October 1–November 24, 2009. MMWR Morb Mortal Wkly Rep 2009;58:1-6. [Ref.ID 87236]

Haug C. The risks and benefits of HPV vaccination. JAMA 2009;302:795-6. [Ref.ID 86576]

10.

Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7. [Ref.ID 86569]

Seleccionar todas

1 a 10 de 10